【个人简介】

博士毕业于复旦大学微生物学专业，随后在复旦大学附属华山医院从事博士后研究，进行新型结核疫苗的研发。2025年10月起任复旦大学感染与健康研究院助理研究员。主要从事结核新型疫苗的研发、宿主免疫应答研究及抗结核策略开发。累计发表SCI论文10余篇，授权发明专1项。

【科研项目与荣誉】

曾获2023年复旦大学超级博士后、2023年国家资助博士后C档；国家重点研发计划（战略性科技创新合作，2025-2028）子任务负责人，主持国家自然科学基金青年基金（2025-2027，30万元）、第76批博士后面上项目（2024-2025，8万元）及静安区博士后创新实践基地项目（2024-2025，32万元）。

【发表论文（部分）】

1. Haibo Su, Shufeng Weng, Liulin Luo, Qin Sun, Taiyue Lin, Huixia Ma, Yumo He, Jing Wu, Honghai Wang, Wenhong Zhang and Ying Xu. 2024. Mycobacterium tuberculosis hijacks host macrophages-derived interleukin 16 to block phagolysosome maturation for enhancing intracellular growth, Emerging Microbes & Infections

2. Weng, Shufeng, Qingchun Li, Tianran Zhang, Taiyue Lin, Yumo He, Guang Yang, Honghai Wang, and Ying Xu. 2024. Enhanced Glycosylation Caused by Overexpression of Rv1002c in a Recombinant BCG Promotes Immune Response and Protects against Mycobacterium tuberculosis Infection, Vaccines

3. Shufeng Weng, Huixia Ma, Taiyue Lin, Yumo He, Jinyi Zhang, Xuelian Zhang, Honghai Wang, Wenhong Zhang, Ying Xu. 2023, Mycobacterium tuberculosis Mce2D protein blocks M1 polarization in macrophages by inhibiting the ERK signaling pathway,Microbial Pathogenesis

4. Zhu, Z., Weng, S., Zheng, F. (2023). Identification of Poly(ADP-ribose) Polymerase 9 (PARP9) as a Potent Suppressor for Mycobacterium tuberculosis Infection. Phenomics

5. Weng S, Zhang J, Ma H, Zhou J, Jia L, Wan Y, Cui P, Ruan Q, Shao L, Wu J, Wang H, Zhang W and Xu Y (2022) B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latent Mycobacterium tuberculosis infection. Front. Immunol.